Malaysia faces a mounting public health crisis as cardio-renal-metabolic diseases—encompassing heart disease, kidney failure and diabetes—accelerate across the population at unprecedented rates. The National Cancer Society Malaysia has responded by calling for an urgent, coordinated national screening programme designed to detect these interconnected conditions earlier and strengthen how patients move through the healthcare system once identified. The appeal comes amid evidence that current medical approaches treat these conditions in isolation, missing critical opportunities to intervene when patients still have time to reverse or slow progression.
Data from a significant community screening initiative illustrates the scale of the challenge confronting Malaysia's health authorities. The NCSM-Boehringer Ingelheim Saring@Komuniti Project, conducted with Ministry of Health support, evaluated 5,000 residents from disadvantaged areas in the Klang Valley and uncovered a troubling picture of overlapping disease burden. Nearly all participants—97.8 per cent—carried at least one cardio-renal-metabolic risk factor. When researchers examined specific conditions, the results were sobering: 41.3 per cent met the clinical definition of obesity, while a further 28.8 per cent were classified as overweight. Blood sugar control emerged as particularly problematic, with 34.5 per cent showing pre-diabetic glucose levels and 35.1 per cent already diagnosed with diabetes. These figures suggest a largely hidden epidemic affecting millions of ordinary Malaysians who may not recognise their vulnerability.
The interconnected nature of these diseases distinguishes them from the isolated health threats that dominated previous generations' concerns. Cardiovascular disease, chronic kidney disease and diabetes do not merely coexist by chance in affected individuals; they actively accelerate one another's progression through shared biological pathways. A person with high blood pressure, for instance, simultaneously damages the heart's ability to pump efficiently and impairs kidney filtration, while their elevated glucose levels compound both injuries. This cascade effect means that a patient developing one condition faces substantially elevated risk of developing the others, yet Malaysia's fragmented health system often addresses each condition separately through different clinics, different medication regimens and different specialist referrals—an approach that leaves patients vulnerable to compounding complications.
The epidemiological trends underpinning NCSM's alarm have worsened dramatically in recent years, suggesting that Malaysia's chronic disease burden will intensify unless preventive action accelerates. Chronic kidney disease prevalence nearly doubled within a single decade, rising from 9.1 per cent in 2011 to 15.5 per cent in 2019. Even more striking, the number of Malaysians requiring dialysis—the most expensive and burdensome form of kidney disease management—has more than tripled over twenty years. These statistics point towards a future where expanding dialysis capacity will consume an ever-larger share of healthcare budgets, diverting resources from earlier prevention. For policymakers, the mathematics are stark: preventing disease progression through early detection costs substantially less than managing advanced complications through intensive interventions.
Current medical practice in Malaysia largely treats cardiovascular, renal and metabolic conditions as separate diseases requiring separate screening programmes, specialist consultations and medication regimens. This fragmentation creates multiple problems simultaneously. Physicians may identify one condition without recognising underlying risk factors for others, allowing preventable progression to accelerate. Patients face confusing referral pathways, inconsistent follow-up schedules and barriers to continuity of care—phenomena particularly acute in Malaysia's underserved communities where transportation, workplace flexibility and health literacy constrain engagement with healthcare systems. A person screened and found to have pre-diabetes, for instance, might receive referral letters to endocrinology but never receive systematic blood pressure or kidney function monitoring that might prevent cardiovascular or renal complications from developing. This systemic fragmentation essentially guarantees that many patients will progress from early, treatable disease to advanced, expensive complications simply because nobody connected the dots.
In response, NCSM has released detailed policy briefs establishing a roadmap for systemic change centred on two foundational principles. First, Malaysia must dramatically expand integrated co-screening programmes that simultaneously assess cardiovascular, kidney and metabolic health through standardised risk assessment tools embedded into routine primary healthcare encounters. Rather than requiring separate appointments for blood pressure screening, lipid panels, kidney function tests and glucose monitoring—each arranged through different channels—patients would receive comprehensive cardio-renal-metabolic evaluation in a single visit, with results interpreted through an integrated lens that recognises disease interconnections. This approach would substantially increase detection rates while reducing the time between abnormal findings and appropriate intervention.
Second, the policy recommendations emphasise strengthening the care continuum that bridges screening and long-term management. In practice, this means establishing standardised referral protocols, dedicated follow-up mechanisms and care coordination systems ensuring that patients discovered through screening actually receive diagnosis confirmation, treatment initiation and sustained disease management rather than simply receiving a report and being discharged back to their general practitioner. Many Malaysian patients currently fall through gaps in the system after abnormal screening results, particularly those from lower socioeconomic backgrounds unfamiliar with navigating specialist referrals. Creating dedicated coordinators or community health workers charged with ensuring continuity—from screening through confirmed diagnosis and ongoing care—would transform screening from a mere diagnostic exercise into the beginning of genuine disease management.
Implementing this integrated strategy would require substantial reorganisation of Malaysia's healthcare delivery architecture. Ministry of Health primary clinics would need standardised protocols for cardio-renal-metabolic risk assessment, consistent across all facilities rather than varying by district. Laboratory services would require enhanced capacity to process the increased volume of tests generated by comprehensive screening. Specialist referral pathways would need clarification and streamlining, with clear protocols determining which patients require cardiologist versus nephrologist versus endocrinologist consultation and in what sequence. Training programmes would need to familiarise primary care physicians with integrated cardio-renal-metabolic assessment rather than disease-specific evaluation. These systemic changes demand investment and political will, yet represent investments in prevention that generate returns far exceeding their costs when measured against the expense of managing advanced disease.
Dr Murallitharan Munisamy, Managing Director of NCSM, emphasised that Malaysia possesses genuine opportunity to transform its chronic disease trajectory by shifting from compartmentalised disease management towards integrated cardio-renal-metabolic care. His statement captures the policy window that the epidemiological data has opened: Malaysia is not yet at the point where the vast majority of the population carries advanced, irreversible chronic disease, but that moment approaches rapidly without preventive intervention. Early detection aligned with coordinated follow-up and sustained long-term management could substantially alter outcomes for millions of Malaysians, reducing disability, extending working years and containing healthcare costs that would otherwise overwhelm the system within decades.
Boehringer Ingelheim Malaysia, the biopharmaceutical company that partnered with NCSM on the Saring@Komuniti screening project, characterised cardiovascular, kidney and metabolic conditions as fundamentally interconnected phenomena that amplify each other's severity. This framing—treating them as an integrated disease cluster rather than three separate conditions—represents the conceptual shift that must underpin Malaysia's policy response. Companies developing therapeutic interventions increasingly recognise that patients with overlapping conditions require integrated treatment strategies addressing all components simultaneously rather than sequential monotherapy targeting individual diseases. Healthcare policy must evolve in the same direction, designing systems that screen for and manage these conditions as the integrated threat they represent rather than as isolated challenges.
For Malaysian policymakers, the evidence supporting integrated cardio-renal-metabolic screening and management strategies continues mounting while implementation remains fragmented and piecemeal. The NCSM findings from underserved Klang Valley communities likely underestimate the problem's magnitude when extrapolated nationally, particularly given that screening focused on relatively accessible urban areas would miss rural and remote populations facing greater structural barriers to healthcare. Without coordinated national action—legislation establishing consistent screening protocols, budget allocation ensuring adequate laboratory and specialist capacity, and training programmes preparing healthcare workers for integrated assessment—Malaysia will continue watching its chronic disease burden expand while the healthcare system struggles to manage late-stage complications rather than preventing disease progression. The policy briefs released by NCSM provide a credible roadmap; implementation depends on whether health authorities and political leaders recognise that prevention through early detection represents not merely a clinical imperative but an economic necessity.
